Aragen Life Sciences

Our business development head for biologics manufacturing, Jamie Cascio, Associate Vice President, will be attending BioEurope from November 4–6, 2024 at Stockholm, Sweden. At Aragen, we specialize in transforming complex R&D challenges into innovative biologics solutions. With over two decades of expertise, we offer end-to-end services in large molecule research, development, and manufacturing. Our state-of-the-art manufacturing facility is designed with scalable single-use bioreactors (from 50L up to 2KL) and advanced technologies to support high-yield production with precision. From process optimization to regulatory submissions, our integrated approach ensures quality, flexibility, and speed for every project. Whether it’s developing new biologics, optimizing manufacturing processes, or managing regulatory submissions, we are committed to being your preferred partner, from concept to market. To schedule a meeting and explore partnering opportunities, write to us at info@aragen.com #drugmanufacting #biologics #drugdevelopment #events2024 #cdmo #cro #pharmaservices #sweden

We’re excited to share that Dr. D.Vijaya Bharathi and Biswadeb Das will represent Aragen at Extractables & Leachables Europe from 4-6 November 2024 in Vienna, Austria. At Aragen, we have developed robust methodologies to design and execute extractables and leachables (E&L) studies for various drug products and packaging materials. From primary packaging materials to injectable, ophthalmic, and vaccine products, our specialized team uses advanced analytical techniques like LC-MS/MS, ICP-MS, and GC-MS to ensure regulatory-compliant results. With a track record of successful global submissions, we ensure your products meet safety standards at every stage. Write to us at info@aragen.com to schedule a meeting with our experts. #analyticalsolutions #chemicalservices #events2024 #cdmo #cro #drugdiscovery #drugmanufacturing #europe #austria

We are thrilled to announce our participation at the 16th Annual PEGS Europe from November 5-7, 2024, in Barcelona, Spain. At Aragen, we excel in protein expression and purification, handling everything from monoclonal antibodies to complex fusion proteins. Our comprehensive Gene to Protein service delivers proteins and antibodies up to grams scale with precise activity and purity. Utilizing versatile mammalian expression systems like CHO-S and HEK-293, along with efficient purification workflows, we tailor solutions to your scale and timeline needs. Whether you require rapid transient transfections or stable cell line production, we guarantee top purity and biological activity to accelerate your research. For personalized protein solutions, contact us at info@aragen.com to arrange a meeting with our experts. Niharika Vejendla | Ayushi Basu #proteins #monoclonal #drugdevelopment #drugdiscovery #genetogmp #spain #events2024 #cdmo #cro #pharmaservices

#mondaymotivation

Dr. Mukul Pore, Executive Director at Intox Pvt Ltd, will be speaking at the World Vaccine Congress 2024! Join his session on “Regulatory Guidelines and Standards for Vaccine Safety Assessment” on Tuesday, 29th October, from 16:30 to 16:45. We offer comprehensive preclinical safety assessment solutions tailored to the needs of vaccine developers. With extensive expertise in toxicology, immunology, and regulatory compliance, we conduct a wide range of studies, including general toxicology, immunogenicity, and specialized immunotoxicology evaluations. Our services are designed to meet global regulatory standards, ensuring the safety and efficacy of vaccines from the early stages of development to the clinical trial phase. By leveraging advanced scientific methodologies and a dedicated team of experts, support in accelerating the safe development of next-generation vaccines, making us a trusted partner in vaccine safety assessment. Write to us at info@aragen.com to schedule a meeting with our team to discuss our service offerings in more detail. Dr. Mukul Pore, Expert Toxicologist | Ayushi Basu #toxstudies #vaccines #earlydrugservices #drugdiscovery #drugdevelopment #clinicaltrails #vaccinesafety

At Aragen, we leverage our extensive experience in Phosphoramidite Chemistry to deliver custom oligonucleotide solutions for therapeutic and diagnostic applications. As the gold standard method for synthesizing oligonucleotides, Phosphoramidite chemistry enables high-efficiency synthesis of sequences up to 200 base pairs in length. Our Phosphoramidites synthesis can be customized as per customer requirements and can be scaled up from milligram to multi-gram or even larger quantities.  Our team of experienced chemists offer custom modifications such as fluorophores and labels with unmatched precision and quality control.   Partner with us to accelerate your oligo-based research with validated methods, robust capabilities, and a commitment to delivering excellence every step of the way! To discuss our capabilities and explore partnering opportunities, write to us at info@aragen.com .   #chemicalsolutions #chemistryservices #drugdevelopment #drugdiscovery #cdmo #cro #pharma #oligonucleotides

Ivan Millan, Business Development Manager-Preclinical Services, will be attending Immuno US 2024 from 28th – 29th October 2024 at San Diego, California. At Aragen, our decades of expertise in antibody discovery and development have resulted in the production of hundreds of antibodies and proteins used across target validation, screening, structural biology, diagnostics, and therapeutics. With industry-leading hybridoma technology, responsible for 90% of FDA-approved antibodies—we offer a comprehensive approach from immunogen generation to preclinical efficacy testing. Our well-established processes reduce risk and ensure efficient delivery of products that meet your specifications in function, scale, and quality. From concept to IND-enabling studies, our dedicated team collaborates closely to develop tailored solutions, ensuring seamless progression through each stage of antibody development. Together, we deliver success! #events2024 #drugdiscovery #drugdevelopment #drugresearch #indstudies #antibodies #preclinical #immunogen #california

We are excited to share the launch of the first phase of Aragen’s ACE Competency Building Program, with about 90 participants attending the inaugural session in the presence of the leadership team. As part of Aragen’s Continuous Excellence (ACE) journey, this program is designed to further equip employees with skills to drive operational excellence across our labs and manufacturing facilities and inculcate a problem-solving mindset. The launch of this 3-phase capability-building initiative will redefine and institutionalize excellence across all our business units and functions. It will not only enhance individual skills but also directly contribute to boosting operational efficiency, improving yield, reducing cycle time, and fostering sustainable practices. We are excited and looking forward to seeing the impact our participants will make as they implement their learnings in their day-to-day operations contributing to Aragen’s and their individual growth. Congratulations to all participants! Together, we are moving ahead in our journey of excellence.  Chandan Shirbhayye, Suresh Anubolu, Sachin Dharap, Naveen Kumar, Yogesh Ranaware, Swapnil Wadhwa Chief Digital Officer, Shanavas Alikunju, PhD & Rahul deb Mondal #sixsigma #leantraining #upskilling #employeeupskilling #trainingprogram #operationalexcellence #competencybuilding #teamwork

We are excited to be at the Society for Immunotherapy of Cancer 2024, from 6th to 10th November 2024 at Houston, booth no. 1041. Aragen offers an extensive range of preclinical oncology models and services, tailored to meet your unique study requirements. Our capabilities include human xenograft tumor models, sub-renal capsule, patient-derived xenograft (PDX), and syngeneic tumor models, enabling detailed evaluation of potential anticancer agents. We closely monitor PK/PD correlations, tumor response, and biomarker analysis to deliver valuable insights. With deep expertise in humanized mouse models, CAR T-cell evaluations, and advanced flow cytometry for detecting tumor-specific antigens, our team supports your preclinical research from design through execution—accelerating your path to clinical development. Partner with us to navigate complex oncology research and reach your milestones faster, write to us at info@aragen.com to schedule a meeting with our experts. Chassidy Hall, Linh Nguyen and Jada Fernandez #oncologyservices #drugdevelopment #drugresearch #tcells #clinical #cancerstudies #preclinicalmodels #cdmo #cro #pharmaservices #endtoendsolutions

As part of our leadership nurturing initiative, we recently had Dr. Robert (Bob) R Ruffolo, former President of R&D at Wyeth and currently a member of Aragen’s Board, talk about how to be a successful leader and share his leadership experiences. Speaking about essential leadership qualities, Bob highlighted that leaders should be passionate, take decisions, be realistically optimistic, unify the team with a single vision and bring out the best within each team member. He emphasised that a true leader builds sustainable processes and teams and not individual success stories. Bob also shared his experiences in turning around Wyeth’s R&D operations and making it a powerhouse in the global pharma industry. He spoke about the challenges faced during the transformation journey and how he overcame them without losing focus on his goals and won the trust of his team members. He also ushered in new trends in the industry such as outsourcing Clinical Data Management and setting up India’s first dedicated R&D center at Aragen (GVB Bio back then). It is our privilege to have Bob as an esteemed member of our Board and be guided by his visionary leadership. Manni Kantipudi, Bob Ruffolo, Suresh Anubolu and Padmaja Naraharisetty #leadersconnect #pharmaleaders #cdmo #cro #clinical #drugdevelopment #drugdiscovery